Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
复制标题
用于胶质母细胞瘤过继细胞治疗的抗 EGFRvIII 嵌合抗原受体修饰 T 细胞。
DOI：
10.2174/1381612823666170316125402
复制
发表时间：
2017
影响因子：
3.1
通讯作者：
Han SY
中科院分区：
文献类型：
--
作者：
Ren PP;Li M;Li TF;Han SY
胶质母细胞瘤（GBM）是一种预后差、死亡率高的恶性肿瘤。虽然根治性手术治疗与随后的放疗和化疗可以提高生存率，但这种方案的疗效是不够的，因为GBM细胞可以扩散并破坏正常的脑结构。此外，这些非特异性治疗可能会损害邻近的健康脑组织。因此，迫切需要开发新的疗法来精确靶向侵袭性肿瘤细胞而不损伤正常组织。免疫治疗是一种很有前途的方法，因为它能够在临床前模型和临床试验中抑制各种肿瘤的生长。使用嵌合抗原受体（CAR）工程化的T细胞的连续性细胞疗法（ACT）靶向GBM中的理想分子标志物，例如表皮生长因子受体III型（EGFRvIII），已经证明在治疗恶性脑肿瘤中具有令人满意的功效。本文综述了近年来利用CAR修饰的EGFRvIII靶向T细胞免疫治疗GBM的研究进展。
Glioblastoma (GBM) is one of the most devastating brain tumors with poor prognosis and high mortality. Although radical surgical treatment with subsequent radiation and chemotherapy can improve the survival, the efficacy of such regimens is insufficient because the GBM cells can spread and destroy normal brain structures. Moreover, these non-specific treatments may damage adjacent healthy brain tissue. It is thus imperative to develop novel therapies to precisely target invasive tumor cells without damaging normal tissues. Immunotherapy is a promising approach due to its capability to suppress the growth of various tumors in preclinical model and clinical trials. Adoptive cell therapy (ACT) using T cells engineered with chimeric antigen receptor (CAR) targeting an ideal molecular marker in GBM, e.g. epidermal growth factor receptor type III (EGFRvIII) has demonstrated a satisfactory efficacy in treating malignant brain tumors. Here we summarize the recent progresses in immunotherapeutic strategy using CAR-modified T cells oriented to EGFRvIII against GBM.